Abstract
To the Editor: We congratulate Walmsley and Sumithran1 for their excellent review on medications for the management of obesity in adults. We also wish to highlight a safety signal for thyroid cancer with glucagon-like peptide 1 (GLP-1) receptor agonists, which is a relevant issue to prescribers given the widespread use of these agents for obesity.
Preclinical studies in rodents demonstrated that all GLP-1 receptor agonists caused thyroid C cell tumours...
Preclinical studies in rodents demonstrated that all GLP-1 receptor agonists caused thyroid C cell tumours...
| Original language | English |
|---|---|
| Pages (from-to) | 187 |
| Number of pages | 1 |
| Journal | Medical Journal of Australia |
| Volume | 219 |
| Issue number | 4 |
| Early online date | 4 Jul 2023 |
| DOIs | |
| Publication status | Published - Aug 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adverse events
- Cancer
- Diabetes mellitus, type 2
- Endocrine gland neoplasms
- Obesity
- Pharmaceuticals
Fingerprint
Dive into the research topics of 'Current and emerging medications for the management of obesity in adults'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver